BioCryst Pharmaceuticals Inc. (BCRX)

8.26
NASDAQ : Health Technology
Prev Close 8.59
Day Low/High 8.18 / 8.75
52 Wk Low/High 4.25 / 9.71
Avg Volume 552.80K
Exchange NASDAQ
Shares Outstanding 109.64M
Market Cap 980.19M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioCryst Pharmaceuticals Announces Termination Of Merger Agreement With Idera Pharmaceuticals

BioCryst Pharmaceuticals Announces Termination Of Merger Agreement With Idera Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst") today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc.

Interesting BCRX Call Options For August 17th

Interesting BCRX Call Options For August 17th

Investors in BioCryst Pharmaceuticals Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BCRX options chain for the new August 17th contracts and identified the following call contract of particular interest.

Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.

Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.

GREENWICH, Conn., June 20, 2018 /PRNewswire/ -- Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc.

BioCryst Issues Letter To Stockholders Reiterating Upside Potential Of Value-Enhancing Merger With Idera

BioCryst Issues Letter To Stockholders Reiterating Upside Potential Of Value-Enhancing Merger With Idera

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company"), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued an open letter to stockholders in connection with the...

Interesting BCRX Call Options For July 20th

Investors in BioCryst Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BCRX options chain for the new July 20th contracts and identified the following call contract of particular interest.

First Week Of BCRX December 21st Options Trading

Investors in BioCryst Pharmaceuticals Inc saw new options become available this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

BioCryst Pharmaceuticals Files Definitive Proxy Statement In Connection With Pending Merger With Idera Pharmaceuticals

BioCryst Pharmaceuticals Files Definitive Proxy Statement In Connection With Pending Merger With Idera Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst") today announced that it has filed definitive proxy materials with the U.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Commit To Buy BioCryst Pharmaceuticals At $4, Earn 18.9% Annualized Using Options

Commit To Buy BioCryst Pharmaceuticals At $4, Earn 18.9% Annualized Using Options

Investors eyeing a purchase of BioCryst Pharmaceuticals Inc shares, but tentative about paying the going market price of $5.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $4 strike, which has a bid at the time of this writing of 40 cents.

Short Interest In BioCryst Pharmaceuticals Declines 10.4%

Short Interest In BioCryst Pharmaceuticals Declines 10.4%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,253,497 share decrease in total short interest for BioCryst Pharmaceuticals Inc , to 10,761,505, a decrease of 10.43% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

RSI Alert: BioCryst Pharmaceuticals Now Oversold

RSI Alert: BioCryst Pharmaceuticals Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Short Interest Jumps 11% For BCRX

Short Interest Jumps 11% For BCRX

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,191,695 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,007,211, an increase of 11.02% since 11/15/2017.

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options

Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: D- (Sell)